As previously reported, Amgen sought leave to appeal a decision of the Federal Court of Appeal (2020 FCA 188) affirming Justice Southcott’s decision that the relevant claims of its filgrastim (NEUPOGEN) patent were invalid for obviousness. On July 9, 2021, the Supreme Court of Canada denied leave to Amgen (Docket No. 39530).
Amgen has discontinued its pending patent infringement actions under the PMNOC Regulations against biosimilar manufacturers Mylan (FULPHILA), Purdue Pharma (PELMEG), and Sandoz (ZIEXTENZO).